TAT-RasGAP<sub>317-326</sub>kills cells by targeting inner-leaflet–enriched phospholipids
Marc Serulla(University of Lausanne), Gabriel Ichim(Université Claude Bernard Lyon 1), Filip Stojceski(University of Applied Sciences and Arts of Southern Switzerland), Gianvito Grasso(University of Applied Sciences and Arts of Southern Switzerland), Sergii Afonin(Karlsruhe Institute of Technology), Mathieu Heulot(University of Lausanne), Tim Schober(Karlsruhe Institute of Technology), Robyn Roth(Washington University in St. Louis), Cédric Godefroy(Centre National de la Recherche Scientifique), Pierre‐Emmanuel Milhiet(Centre National de la Recherche Scientifique), Kushal Kumar Das(University of Tübingen), Ana J. García‐Sáez(University of Tübingen), Andrea Danani(University of Applied Sciences and Arts of Southern Switzerland), Christian Widmann(University of Lausanne)
Cited by 29Open Access
Abstract
Significance TAT-RasGAP 317–326 can lyse cancer cells in a manner distinct from known programmed cell death pathways through its ability to target specific plasma membrane lipids. The killing properties of this peptide may therefore be difficult for cancer cells to alleviate through resistance-building alterations within known regulated cell death pathways. TAT-RasGAP 317–326 and compounds with similar anticancer activities can potentially complement existing anticancer therapies based on the use of genotoxins or radiation that induce apoptosis.
Related Papers
No related papers found
Powered by citation graph analysis